Sign In
Buy SILO
$4.19
-0.0600 (-1.41%)
At Close: Jul 31, 2026
Short Interest in Silo Pharma, Inc. (NASDAQ:SILO) Expands By 795.6%
04:02am, Monday, 27'th Jul 2026
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) was the recipient of a large increase in short interest in July. As of July 15th, there was short interest totaling 155,110 shares, an increase of 79
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
08:55am, Tuesday, 21'st Jul 2026
Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate
Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership
11:45am, Tuesday, 14'th Jul 2026
Silo Pharma Incs (NASDAQ:SILO) announced on Tuesday that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices Inc.'s (NASDAQ:AMD) AI Developer Program, providing acce
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
08:55am, Tuesday, 14'th Jul 2026
Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents Access to AMD Developer Cloud credits, AI development tools and tech
Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
08:00am, Friday, 10'th Jul 2026
$4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon the exercise in full of warrants in cash
Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives
02:18pm, Tuesday, 07'th Jul 2026
NVIDIA Corp. (NASDAQ:NVDA) expanded its presence in life sciences AI through separate initiatives with Certara Inc. (NASDAQ:CERT) and Silo Pharma Inc. (NASDAQ:SILO).
Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
08:11am, Tuesday, 07'th Jul 2026
NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing
Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
04:15pm, Monday, 29'th Jun 2026
Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
08:17am, Tuesday, 23'rd Jun 2026
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA. , June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) ("Sil
Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
08:12am, Thursday, 18'th Jun 2026
SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug d
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
08:05am, Thursday, 07'th May 2026
New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines
Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
09:08am, Wednesday, 29'th Apr 2026
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment
Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
09:08am, Wednesday, 29'th Apr 2026
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment SARASOTA, Fla, April 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharm
Silo Pharma, Inc. (NASDAQ:SILO) Short Interest Update
05:38am, Monday, 27'th Apr 2026
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 522,541 share
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO
